Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MIC-Lx
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection
Details : The so-called TOL-1 study met all endpoints and demonstrated the feasibility and safety of MIC-Lx administration in inducing donor-specific tolerance in kidney transplant recipients.
Product Name : MIC-Lx
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : MIC-Lx
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable